Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Impact of Caffeine on the Blood Stem Cells in Healthy Adults

Official title: CaffeineHSC - Effect of Chronic Caffeine Consumption and Acute Caffeine Administration on the Hematopoietic System

Run by ETH Zurich · NCT07193264 · Data updated 2026-11-12

This study tests whether a single 200 mg dose of caffeine changes blood stem and progenitor cells in healthy adults who regularly drink caffeine compared with those who rarely or never do.

More Hematopoietic and Lymphatic System Neoplasm trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorETH Zurich
Academic / other
Drugs / interventionsradiation
Locations2 sites (Zurich, Canton of Zurich and 1 other locations)
StatusRecruiting
StartedNovember 5, 2025
Main results expectedDecember 2027
Study endsJune 2028
Registry record updatedJuly 6, 2026
Trial IDNCT07193264 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Healthy adults aged 18 years and older who regularly consume caffeine or consume very little/none for at least 6 months and can fast for the study.

Probably not a fit

People with chronic illnesses, hematologic disorders, or those who cannot fast or have caffeine intolerance are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study administers a single 200 mg caffeine tablet to healthy adult participants under fasting conditions to examine its effects on blood hematopoietic cells. Participants are grouped by regular caffeine consumption versus minimal/no intake and blood samples are collected before and three hours after dosing. Outcomes include changes in mobilization of stem and progenitor cells from bone marrow into the bloodstream, as well as effects on cell function, gene activity, and metabolism. The trial uses a controlled, single-dose design with translational measurements in human subjects to understand caffeine’s immediate hematopoietic effects.

Why it matters

Potential benefit: If successful, findings may clarify how caffeine could influence blood cell biology in healthy individuals.

How similar studies have gone: Previous research in humans has explored caffeine’s systemic effects, but studies directly linking caffeine to hematopoietic cell mobilization and function are limited and largely exploratory.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Able to give consent.
* Healthy adults aged ≥ 18 years.
* Regular caffeine consumers (≥1 coffee cup/day or ≥1 energy drink/day) or non-consumers (≤1 cup/month and ≤1 energy drink/month) for at least 6 months.
* Willingness to comply with fasting requirements and study procedures.

Exclusion Criteria:

* Chronic illnesses or medication use affecting metabolism, including metabolic disorders (e.g., diabetes, thyroid dysfunction, metabolic syndrome).
* Personal history of cancer.
* Personal history of hematological disorders.
* History of radiation therapy.
* Known caffeine hypersensitivity or intolerance.
* Known immunosuppression.

Where it's running

  • Eth Glc
    Zurich, Canton of Zurich, Switzerland
    Recruiting
  • Eth Glc
    Zurich, Canton of Zurich, Switzerland
    Not yet recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.